Close Menu

NEW YORK – NeoGenomics announced on Tuesday a partnership with Lilly Oncology aimed at molecular testing for thyroid cancer patients. 

Through the Thyroid Cancer Testing Program, sponsored by Lilly Oncology, NeoGenomics will offer patients in the program either the NGS Thyroid Profile test for metastatic medullary thyroid cancer patients, or the NGS Thyroid Profile plus RET FISH test for non-metastatic medullary thyroid cancer patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.